Portfolio

Zimmer BioTech

As early as 2012, Zimmer contributed to the development of a drug based on the compound 5-Aminolevulinic acid for use in the treatment of actinic keratoses. The spin-off Zimmer BioTech has been active since October 2016 and is funded by Bonn-based High-Tech Gründerfonds, Germany’s largest seed stage investor. Alevin deep, the first drug to be developed by Zimmer BioTech, is expected to receive approval by 2020.

Info & Contact

Phone:
+49 7 3197610
Web:
zimmer.de

Address

Zimmer MedizinSysteme GmbH
Junkersstraße 9
89231 Neu-Ulm

In portfolio

13. Jun 2017